메뉴 건너뛰기




Volumn 78, Issue 1, 2016, Pages 119-130

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer

Author keywords

Advanced colorectal cancer; Clinical efficacy; Han nationality; Irinotecan based chemotherapy; Polymorphism; Toxicity; UGT1A1; Uygur nationality

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; TETRAHYDROFOLIC ACID; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE; URIDINE DIPHOSPHATE GLUCORONOSYLTRANSFERASE 1A1; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

EID: 84970027686     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-016-3057-z     Document Type: Article
Times cited : (39)

References (47)
  • 2
    • 84940173230 scopus 로고    scopus 로고
    • Incidence and mortality of colorectal cancer in China, 2011
    • PID: 25717222
    • Liu S, Zheng R, Zhang M et al (2015) Incidence and mortality of colorectal cancer in China, 2011. Chin J Cancer Res 27:22–28
    • (2015) Chin J Cancer Res , vol.27 , pp. 22-28
    • Liu, S.1    Zheng, R.2    Zhang, M.3
  • 3
    • 84958940813 scopus 로고    scopus 로고
    • Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer
    • Morand Bounaix, du Puch C, Nouaille M, Giraud S et al (2016) Chemotherapy outcome predictive effectiveness by the Oncogramme: pilot trial on stage-IV colorectal cancer. J Transl Med 14:10
    • (2016) J Transl Med , vol.14 , pp. 10
    • Morand, B.1    du Puch, C.2    Nouaille, M.3    Giraud, S.4
  • 4
    • 84922754254 scopus 로고    scopus 로고
    • A review of the evolution of systemic chemotherapy in the management of colorectal cancer
    • COI: 1:CAS:528:DC%2BC2MXovVyhsbk%3D, PID: 25579803
    • Gustavsson B, Carlsson G, Machover D et al (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer 14:1–10
    • (2015) Clin Colorectal Cancer , vol.14 , pp. 1-10
    • Gustavsson, B.1    Carlsson, G.2    Machover, D.3
  • 5
    • 84951827874 scopus 로고    scopus 로고
    • Pharmacologic resistance in colorectal cancer: a review
    • COI: 1:CAS:528:DC%2BC28XotValsrk%3D, PID: 26753006
    • Hammond WA, Swaika A, Mody K (2016) Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol 8:57–84
    • (2016) Ther Adv Med Oncol , vol.8 , pp. 57-84
    • Hammond, W.A.1    Swaika, A.2    Mody, K.3
  • 6
    • 78650233991 scopus 로고    scopus 로고
    • Chemotherapy of metastatic colorectal cancer
    • 19(109):219–224
    • (2010) Chemotherapy of metastatic colorectal cancer. Prescrire Int 19(109):219–224
    • (2010) Prescrire Int
  • 7
    • 84981309787 scopus 로고    scopus 로고
    • Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX
    • Kim MJ, Han SW, Lee DW et al (2016) Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat. doi:10.4143/crt.2015.296
    • (2016) Cancer Res Treat
    • Kim, M.J.1    Han, S.W.2    Lee, D.W.3
  • 8
    • 84893868630 scopus 로고    scopus 로고
    • Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB
    • COI: 1:CAS:528:DC%2BC2cXhtV2ltbg%3D, PID: 24173769
    • Yu M, Tong X, Qi B et al (2014) Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep 9:249–254
    • (2014) Mol Med Rep , vol.9 , pp. 249-254
    • Yu, M.1    Tong, X.2    Qi, B.3
  • 9
    • 78649307699 scopus 로고    scopus 로고
    • Pharmacogenetics of irinotecan disposition and toxicity: a review
    • COI: 1:CAS:528:DC%2BC3cXhtVOmu7%2FI, PID: 20406168
    • Fujita K, Sparreboom A (2010) Pharmacogenetics of irinotecan disposition and toxicity: a review. Curr Clin Pharmacol 5:209–217
    • (2010) Curr Clin Pharmacol , vol.5 , pp. 209-217
    • Fujita, K.1    Sparreboom, A.2
  • 10
    • 33750583902 scopus 로고    scopus 로고
    • Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy
    • PID: 17008691
    • O’Dwyer PJ, Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534–4538
    • (2006) J Clin Oncol , vol.24 , pp. 4534-4538
    • O’Dwyer, P.J.1    Catalano, R.B.2
  • 11
    • 66349133649 scopus 로고    scopus 로고
    • Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
    • COI: 1:CAS:528:DC%2BD1MXmvVOhsL0%3D, PID: 19364970
    • Cecchin E, Innocenti F, D’Andrea M et al (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 27:2457–2465
    • (2009) J Clin Oncol , vol.27 , pp. 2457-2465
    • Cecchin, E.1    Innocenti, F.2    D’Andrea, M.3
  • 12
    • 84948993611 scopus 로고    scopus 로고
    • Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BC28XlvVCqtbs%3D, PID: 26604633
    • Fujita K, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21:12234–12248
    • (2015) World J Gastroenterol , vol.21 , pp. 12234-12248
    • Fujita, K.1    Kubota, Y.2    Ishida, H.3    Sasaki, Y.4
  • 13
    • 84876327926 scopus 로고    scopus 로고
    • Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy
    • COI: 1:CAS:528:DC%2BC3sXktVGisb4%3D, PID: 23303296
    • Inoue K, Sonobe M, Kawamura Y et al (2013) Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 229:107–114
    • (2013) Tohoku J Exp Med , vol.229 , pp. 107-114
    • Inoue, K.1    Sonobe, M.2    Kawamura, Y.3
  • 14
    • 84907451342 scopus 로고    scopus 로고
    • A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes
    • COI: 1:CAS:528:DC%2BC2cXhvFyit7zN, PID: 25175642
    • Tsunedomi R, Hazama S, Fujita Y et al (2014) A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. Int J Oncol 45:1381–1390
    • (2014) Int J Oncol , vol.45 , pp. 1381-1390
    • Tsunedomi, R.1    Hazama, S.2    Fujita, Y.3
  • 15
    • 79960320017 scopus 로고    scopus 로고
    • Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent
    • COI: 1:CAS:528:DC%2BC3MXhtFSrsLnM, PID: 22866151
    • Fukui T, Mitsufuji H, Kubota M et al (2011) Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett 2:923–928
    • (2011) Oncol Lett , vol.2 , pp. 923-928
    • Fukui, T.1    Mitsufuji, H.2    Kubota, M.3
  • 16
    • 12244271026 scopus 로고    scopus 로고
    • Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups
    • COI: 1:CAS:528:DC%2BD38XptFOqsbg%3D, PID: 12464801
    • Innocenti F, Grimsley C, Das S et al (2002) Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12:725–733
    • (2002) Pharmacogenetics , vol.12 , pp. 725-733
    • Innocenti, F.1    Grimsley, C.2    Das, S.3
  • 17
    • 14044279224 scopus 로고    scopus 로고
    • Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American
    • COI: 1:CAS:528:DC%2BD2MXisFSgt74%3D, PID: 15572581
    • Kaniwa N, Kurose K, Jinno H et al (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab Dispos 33:458–465
    • (2005) Drug Metab Dispos , vol.33 , pp. 458-465
    • Kaniwa, N.1    Kurose, K.2    Jinno, H.3
  • 18
    • 85027955716 scopus 로고    scopus 로고
    • The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions
    • COI: 1:CAS:528:DC%2BC3cXpt1yru7w%3D, PID: 20511137
    • Marques SC, Ikediobi ON (2010) The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions. Hum Genomics 4:238–249
    • (2010) Hum Genomics , vol.4 , pp. 238-249
    • Marques, S.C.1    Ikediobi, O.N.2
  • 19
    • 84897383948 scopus 로고    scopus 로고
    • Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
    • COI: 1:CAS:528:DC%2BC3sXksFOlsL4%3D, PID: 23529007
    • Liu X, Cheng D, Kuang Q, Liu G, Xu W (2014) Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 14:120–129
    • (2014) Pharmacogenomics J , vol.14 , pp. 120-129
    • Liu, X.1    Cheng, D.2    Kuang, Q.3    Liu, G.4    Xu, W.5
  • 20
    • 84893319290 scopus 로고    scopus 로고
    • The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis
    • COI: 1:CAS:528:DC%2BC2cXhs1Wnsb4%3D, PID: 24308720
    • Chen YJ, Hu F, Li CY et al (2014) The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians: a meta-analysis. Biomarkers 19:56–62
    • (2014) Biomarkers , vol.19 , pp. 56-62
    • Chen, Y.J.1    Hu, F.2    Li, C.Y.3
  • 21
    • 0038351780 scopus 로고    scopus 로고
    • The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications
    • COI: 1:CAS:528:DC%2BD3sXlt1aqsrk%3D, PID: 12850492
    • Premawardhena A, Fisher CA, Liu YT et al (2003) The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 31:98–101
    • (2003) Blood Cells Mol Dis , vol.31 , pp. 98-101
    • Premawardhena, A.1    Fisher, C.A.2    Liu, Y.T.3
  • 22
    • 34748857912 scopus 로고    scopus 로고
    • Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations
    • COI: 1:CAS:528:DC%2BD2sXhtVOrtLnN, PID: 17060921
    • Zhang A, Xing Q, Qin S et al (2007) Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations. Pharmacogenomics J 7:333–338
    • (2007) Pharmacogenomics J , vol.7 , pp. 333-338
    • Zhang, A.1    Xing, Q.2    Qin, S.3
  • 23
    • 34250665419 scopus 로고    scopus 로고
    • Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer
    • COI: 1:CAS:528:DC%2BD2sXnvFKnsb0%3D, PID: 17406868
    • Fujita K, Ando Y, Nagashima F et al (2007) Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 60:515–522
    • (2007) Cancer Chemother Pharmacol , vol.60 , pp. 515-522
    • Fujita, K.1    Ando, Y.2    Nagashima, F.3
  • 24
    • 84889593378 scopus 로고    scopus 로고
    • UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan
    • COI: 1:CAS:528:DC%2BC3sXhvVyksrbE, PID: 24033692
    • Hazama S, Mishima H, Tsunedomi R et al (2013) UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci 104:1662–1669
    • (2013) Cancer Sci , vol.104 , pp. 1662-1669
    • Hazama, S.1    Mishima, H.2    Tsunedomi, R.3
  • 25
    • 84953343664 scopus 로고    scopus 로고
    • UGT1A1 genotyping for proper use of irinotecan
    • PID: 26591441
    • Matsuoka A, Ando Y (2015) UGT1A1 genotyping for proper use of irinotecan. Rinsho Byori 63:876–882
    • (2015) Rinsho Byori , vol.63 , pp. 876-882
    • Matsuoka, A.1    Ando, Y.2
  • 26
    • 0030693602 scopus 로고    scopus 로고
    • Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study
    • COI: 1:STN:280:DyaK1c%2FgtVOmtQ%3D%3D, PID: 9382402
    • Cleeland CS, Gonin R, Baez L, Loehrer P, Pandya KJ (1997) Pain and treatment of pain in minority patients with cancer. The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Ann Intern Med 127:813–816
    • (1997) Ann Intern Med , vol.127 , pp. 813-816
    • Cleeland, C.S.1    Gonin, R.2    Baez, L.3    Loehrer, P.4    Pandya, K.J.5
  • 27
    • 4344702304 scopus 로고    scopus 로고
    • Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0
    • PID: 15332541
    • Kaba H, Fukuda H, Yamamoto S, Ohashi Y (2004) Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho 31:1187–1192
    • (2004) Gan To Kagaku Ryoho , vol.31 , pp. 1187-1192
    • Kaba, H.1    Fukuda, H.2    Yamamoto, S.3    Ohashi, Y.4
  • 28
    • 77955591119 scopus 로고    scopus 로고
    • Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know
    • PID: 20651182
    • Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 195:281–289
    • (2010) AJR Am J Roentgenol , vol.195 , pp. 281-289
    • Nishino, M.1    Jagannathan, J.P.2    Ramaiya, N.H.3    Van den Abbeele, A.D.4
  • 29
    • 84949680996 scopus 로고    scopus 로고
    • The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer
    • PID: 26664141
    • Xiao XG, Xia S, Zou M et al (2015) The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther 8:3575–3583
    • (2015) Onco Targets Ther , vol.8 , pp. 3575-3583
    • Xiao, X.G.1    Xia, S.2    Zou, M.3
  • 30
    • 84876711885 scopus 로고    scopus 로고
    • UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer
    • COI: 1:CAS:528:DC%2BC3sXktFekt7c%3D, PID: 22934695
    • Zhou CF, Ma T, Su Y et al (2013) UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem 13:235–241
    • (2013) Anticancer Agents Med Chem , vol.13 , pp. 235-241
    • Zhou, C.F.1    Ma, T.2    Su, Y.3
  • 31
    • 84908667178 scopus 로고    scopus 로고
    • Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs
    • Chantry AS, Quaranta S, Ciccolini J, Lacarelle B (2014) Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs. Ann Biol Clin (Paris) 72:527–542
    • (2014) Ann Biol Clin (Paris) , vol.72 , pp. 527-542
    • Chantry, A.S.1    Quaranta, S.2    Ciccolini, J.3    Lacarelle, B.4
  • 32
    • 85006186477 scopus 로고    scopus 로고
    • PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BC28XlslWitb0%3D, PID: 26806397
    • Chibaudel B, Maindrault-Goebel F, Bachet JB et al (2016) PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. Cancer Med 5:676–683
    • (2016) Cancer Med , vol.5 , pp. 676-683
    • Chibaudel, B.1    Maindrault-Goebel, F.2    Bachet, J.B.3
  • 33
    • 26444594410 scopus 로고    scopus 로고
    • Clinical pharmacogenetics of irinotecan (CPT-11)
    • COI: 1:CAS:528:DC%2BD2MXhtFyqu7fF, PID: 16257834
    • Ando Y, Hasegawa Y (2005) Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab Rev 37:565–574
    • (2005) Drug Metab Rev , vol.37 , pp. 565-574
    • Ando, Y.1    Hasegawa, Y.2
  • 34
    • 84902936865 scopus 로고    scopus 로고
    • Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801)
    • COI: 1:CAS:528:DC%2BC2cXhtFOqt7fI, PID: 24968756
    • Soeda H, Shimodaira H, Gamoh M et al (2014) Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). Oncology 87:7–20
    • (2014) Oncology , vol.87 , pp. 7-20
    • Soeda, H.1    Shimodaira, H.2    Gamoh, M.3
  • 35
    • 84896051392 scopus 로고    scopus 로고
    • UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
    • COI: 1:CAS:528:DC%2BC2cXhtVymt7s%3D, PID: 24448639
    • Cheng L, Li M, Hu J et al (2014) UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 73:551–560
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 551-560
    • Cheng, L.1    Li, M.2    Hu, J.3
  • 36
    • 84873906813 scopus 로고    scopus 로고
    • UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil
    • COI: 1:CAS:528:DC%2BC38XhvVyisLnP, PID: 23236239
    • Wang Y, Shen L, Xu N et al (2012) UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 18:6635–6644
    • (2012) World J Gastroenterol , vol.18 , pp. 6635-6644
    • Wang, Y.1    Shen, L.2    Xu, N.3
  • 37
    • 84957991755 scopus 로고    scopus 로고
    • Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients
    • COI: 1:CAS:528:DC%2BC28Xislakt7k%3D, PID: 26830078
    • Atasilp C, Chansriwong P, Sirachainan E et al (2016) Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients. Drug Metab Pharmacokinet 31:90–94
    • (2016) Drug Metab Pharmacokinet , vol.31 , pp. 90-94
    • Atasilp, C.1    Chansriwong, P.2    Sirachainan, E.3
  • 38
    • 84954076213 scopus 로고    scopus 로고
    • Development of pyrosequencing method for detection of UGT1A1 polymorphisms in thai colorectal cancers
    • COI: 1:CAS:528:DC%2BC28XhtV2jtrs%3D, PID: 25545261
    • Sukasem C, Atasilp C, Chansriwong P et al (2016) Development of pyrosequencing method for detection of UGT1A1 polymorphisms in thai colorectal cancers. J Clin Lab Anal 30:84–89
    • (2016) J Clin Lab Anal , vol.30 , pp. 84-89
    • Sukasem, C.1    Atasilp, C.2    Chansriwong, P.3
  • 39
    • 0028420933 scopus 로고
    • Direct sequencing of PCR-amplified DNA
    • COI: 1:CAS:528:DyaK2MXhsVOruw%3D%3D, PID: 7859155
    • Green PM, Giannelli F (1994) Direct sequencing of PCR-amplified DNA. Mol Biotechnol 1:117–124
    • (1994) Mol Biotechnol , vol.1 , pp. 117-124
    • Green, P.M.1    Giannelli, F.2
  • 40
    • 44849107763 scopus 로고    scopus 로고
    • UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity
    • COI: 1:CAS:528:DC%2BD1cXnvVagurs%3D, PID: 18467239
    • Biason P, Masier S, Toffoli G (2008) UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother 20:158–165
    • (2008) J Chemother , vol.20 , pp. 158-165
    • Biason, P.1    Masier, S.2    Toffoli, G.3
  • 41
    • 84878637878 scopus 로고    scopus 로고
    • Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer
    • COI: 1:CAS:528:DC%2BC3sXovVejs74%3D, PID: 23543295
    • Cortejoso L, Garcia MI, Garcia-Alfonso P et al (2013) Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemother Pharmacol 71:1463–1472
    • (2013) Cancer Chemother Pharmacol , vol.71 , pp. 1463-1472
    • Cortejoso, L.1    Garcia, M.I.2    Garcia-Alfonso, P.3
  • 42
    • 84908159566 scopus 로고    scopus 로고
    • Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BC2cXitFOltbrL, PID: 25285015
    • Li M, Wang Z, Guo J et al (2014) Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 7:1653–1661
    • (2014) Onco Targets Ther , vol.7 , pp. 1653-1661
    • Li, M.1    Wang, Z.2    Guo, J.3
  • 43
    • 84905117637 scopus 로고    scopus 로고
    • Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan
    • COI: 1:CAS:528:DC%2BC2MXovFCitQ%3D%3D, PID: 24977443
    • Boyer JC, Etienne-Grimaldi MC, Thomas F et al (2014) Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan. Bull Cancer 101:533–553
    • (2014) Bull Cancer , vol.101 , pp. 533-553
    • Boyer, J.C.1    Etienne-Grimaldi, M.C.2    Thomas, F.3
  • 44
    • 59849128188 scopus 로고    scopus 로고
    • Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review
    • COI: 1:CAS:528:DC%2BD1MXlvFenuw%3D%3D, PID: 19125129
    • Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD (2009) Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 11:21–34
    • (2009) Genet Med , vol.11 , pp. 21-34
    • Palomaki, G.E.1    Bradley, L.A.2    Douglas, M.P.3    Kolor, K.4    Dotson, W.D.5
  • 45
    • 33745972934 scopus 로고    scopus 로고
    • The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BD28XnslKhs7w%3D, PID: 16809730
    • Toffoli G, Cecchin E, Corona G et al (2006) The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24:3061–3068
    • (2006) J Clin Oncol , vol.24 , pp. 3061-3068
    • Toffoli, G.1    Cecchin, E.2    Corona, G.3
  • 46
    • 73449111242 scopus 로고    scopus 로고
    • UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    • COI: 1:CAS:528:DC%2BD1MXhtlOhtLnM, PID: 19859999
    • Schulz C, Heinemann V, Schalhorn A et al (2009) UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 15:5058–5066
    • (2009) World J Gastroenterol , vol.15 , pp. 5058-5066
    • Schulz, C.1    Heinemann, V.2    Schalhorn, A.3
  • 47
    • 84875024320 scopus 로고    scopus 로고
    • Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians
    • COI: 1:CAS:528:DC%2BC3sXltVSqu74%3D, PID: 23516488
    • Liu X, Cheng D, Kuang Q, Liu G, Xu W (2013) Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians. PLoS ONE 8:e58489
    • (2013) PLoS ONE , vol.8 , pp. e58489
    • Liu, X.1    Cheng, D.2    Kuang, Q.3    Liu, G.4    Xu, W.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.